Healthcare provider profile · identity verified

Mitchell Bober, DO

Allopathic & Osteopathic Physicians|Family Medicine · PENNSVILLE, NJ · NPI 1902805013

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Mitchell Bober, DO received $46.03 in general payments during 2025 across 3 reported records.

AstraZeneca Pharmaceuticals LP accounted for 67.3% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 3 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Paxlovid.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Farxiga by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.

PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 168 claims for Eliquis by this doctor in 2024.

PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Paxlovid by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$46.03

3 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
AstraZeneca Pharmaceuticals LP	Unresolved — no canonical attribution shown	$30.96	67.3%	2	2025
PFIZER INC.	Unresolved — no canonical attribution shown	$15.07	32.7%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$46.03	3

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
AIRSUPRA Normalized: airsupra	Drug	AstraZeneca Pharmaceuticals LP	$15.99	1	2025
Source payment records 2025-01-16 · AstraZeneca Pharmaceuticals LP · $15.99 · Open Payments source
PAXLOVID Normalized: paxlovid	Drug	PFIZER INC.	$15.07	1	2025
Source payment records 2025-01-14 · PFIZER INC. · $15.07 · Open Payments source
FARXIGA Normalized: farxiga	Drug	AstraZeneca Pharmaceuticals LP	$14.97	1	2025
Source payment records 2025-01-22 · AstraZeneca Pharmaceuticals LP · $14.97 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
FARXIGA farxiga	2025	Farxiga	2024	72	exact normalized	Medicare Part D
PAXLOVID paxlovid	2025	Paxlovid	2024	35	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	FARXIGA open payments reported associated product	CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362	Farxiga · 2024 Exact normalized brand match · 1 Part D row	72	23
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	SYMBICORT open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610	Symbicort · 2024 Exact normalized brand match · 1 Part D row	16	suppressed by CMS
PFIZER INC. Exact reporting entity; no affiliate inference	2025	ELIQUIS open payments reported associated product	CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063	Eliquis · 2024 Exact normalized brand match · 1 Part D row	168	44
PFIZER INC. Exact reporting entity; no affiliate inference	2025	PAXLOVID open payments reported associated product	CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432	Paxlovid · 2024 Exact normalized brand match · 1 Part D row	35	34

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Losartan Potassium	Losartan Potassium	1202	292
Atorvastatin Calcium	Atorvastatin Calcium	1003	261
Amlodipine Besylate	Amlodipine Besylate	955	243
Metformin Hcl	Metformin Hcl	677	175
Levothyroxine Sodium	Levothyroxine Sodium	563	142
Metoprolol Succinate	Metoprolol Succinate	556	152
Pantoprazole Sodium	Pantoprazole Sodium	530	144
Glimepiride	Glimepiride	389	102
Omeprazole	Omeprazole	382	102
Lisinopril	Lisinopril	372	102
Pravastatin Sodium	Pravastatin Sodium	362	92
Simvastatin	Simvastatin	316	87
Furosemide	Furosemide	267	81
Citalopram Hbr	Citalopram Hydrobromide	248	56
Rosuvastatin Calcium	Rosuvastatin Calcium	245	70
Doxycycline Hyclate	Doxycycline Hyclate	243	178
Albuterol Sulfate Hfa	Albuterol Sulfate	237	109
Gabapentin	Gabapentin	236	61
Metoprolol Tartrate	Metoprolol Tartrate	223	57
Cefprozil	Cefprozil	203	167
Methylprednisolone	Methylprednisolone	192	155
Hydrochlorothiazide	Hydrochlorothiazide	191	47
Buspirone Hcl	Buspirone Hcl	190	60
Clopidogrel	Clopidogrel Bisulfate	176	44
Eliquis	Apixaban	168	44
Sertraline Hcl	Sertraline Hcl	168	39
Tamsulosin Hcl	Tamsulosin Hcl	166	42
Escitalopram Oxalate	Escitalopram Oxalate	162	45
Allopurinol	Allopurinol	161	41
Meloxicam	Meloxicam	158	95
Januvia	Sitagliptin Phosphate	156	31
Atenolol	Atenolol	150	42
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	133	32
Duloxetine Hcl	Duloxetine Hcl	129	29
Potassium Chloride	Potassium Chloride	128	29
Ezetimibe	Ezetimibe	121	31
Azithromycin	Azithromycin	115	92
Olmesartan Medoxomil	Olmesartan Medoxomil	113	33
Synthroid	Levothyroxine Sodium	113	26
Carvedilol	Carvedilol	105	27
Montelukast Sodium	Montelukast Sodium	104	30
Fenofibrate	Fenofibrate Nanocrystallized	99	27
Alendronate Sodium	Alendronate Sodium	97	22
Esomeprazole Magnesium	Esomeprazole Magnesium	84	24
Mupirocin	Mupirocin	82	68
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	82	62
Lovastatin	Lovastatin	81	21
Ketoconazole	Ketoconazole	79	50
Fluticasone Propionate	Fluticasone Propionate	75	35
Farxiga	Dapagliflozin Propanediol	72	23
Cefdinir	Cefdinir	69	60
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	69	26
Famotidine	Famotidine	68	18
Meclizine Hcl	Meclizine Hcl	68	37
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	66	53
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	66	15
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	64	21
Betamethasone Diprop Augmented	Betamethasone/Propylene Glyc	63	52
Clonidine Hcl	Clonidine Hcl	63	15
Trulicity	Dulaglutide	62	13
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	57	15
Breo Ellipta	Fluticasone/Vilanterol	56	16
Xarelto	Rivaroxaban	56	13
Nifedipine Er	Nifedipine	55	15
Hydroxyzine Pamoate	Hydroxyzine Pamoate	54	25
Paroxetine Hcl	Paroxetine Hcl	54	suppressed
Mounjaro	Tirzepatide	52	12
Venlafaxine Hcl Er	Venlafaxine Hcl	52	13
Ropinirole Hcl	Ropinirole Hcl	51	13
Trazodone Hcl	Trazodone Hcl	49	11
Telmisartan	Telmisartan	48	suppressed
Tresiba Flextouch U-100	Insulin Degludec	48	suppressed
Betamethasone Dipropionate	Betamethasone Dipropionate	45	40
Fenofibrate	Fenofibrate	44	11
Finasteride	Finasteride	44	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	44	39
Cephalexin	Cephalexin	43	40
Isosorbide Mononitrate Er	Isosorbide Mononitrate	42	suppressed
Warfarin Sodium	Warfarin Sodium	42	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	41	18
Tradjenta	Linagliptin	41	suppressed
Glipizide	Glipizide	40	13
Hydralazine Hcl	Hydralazine Hcl	40	12
Valsartan	Valsartan	40	12
Zolpidem Tartrate	Zolpidem Tartrate	40	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	39	suppressed
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	38	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	37	12
Mirtazapine	Mirtazapine	37	suppressed
Diclofenac Sodium	Diclofenac Sodium	36	11
Levetiracetam	Levetiracetam	35	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	35	34
Ozempic	Semaglutide	33	12
Ciprofloxacin Hcl	Ciprofloxacin Hcl	32	26
Colchicine	Colchicine	32	12
Metformin Hcl Er	Metformin Hcl	32	12
Irbesartan	Irbesartan	31	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	31	suppressed
Fluconazole	Fluconazole	30	16
Rabeprazole Sodium	Rabeprazole Sodium	30	suppressed
Prednisone	Prednisone	29	suppressed
Valacyclovir	Valacyclovir Hcl	29	22
Alprazolam	Alprazolam	27	14
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	27	suppressed
Donepezil Hcl	Donepezil Hcl	27	suppressed
Jardiance	Empagliflozin	27	suppressed
Chlorthalidone	Chlorthalidone	26	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	26	suppressed
Amoxicillin	Amoxicillin	25	20
Levofloxacin	Levofloxacin	25	22
Novolog Flexpen	Insulin Aspart	24	suppressed
Spironolactone	Spironolactone	24	suppressed
Naproxen	Naproxen	23	13
Pregabalin	Pregabalin	23	suppressed
Ramipril	Ramipril	23	suppressed
Labetalol Hcl	Labetalol Hcl	22	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	22	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	21	suppressed
Ranolazine Er	Ranolazine	21	suppressed
Celecoxib	Celecoxib	20	suppressed
Ondansetron Odt	Ondansetron	20	12
Bupropion Xl	Bupropion Hcl	19	suppressed
Humalog Kwikpen U-100	Insulin Lispro	19	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	18	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	18	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	18	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	18	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	18	suppressed
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	17	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	17	12
Levemir Flexpen	Insulin Detemir	17	suppressed
Mometasone Furoate	Mometasone Furoate	17	suppressed
Nystatin	Nystatin	17	12
Bumetanide	Bumetanide	16	suppressed
Colesevelam Hcl	Colesevelam Hcl	16	suppressed
Fiasp Flextouch	Insulin Aspart (Niacinamide)	16	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	16	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	16	suppressed
Ofloxacin	Ofloxacin	16	14
Risedronate Sodium	Risedronate Sodium	16	suppressed
Symbicort	Budesonide/Formoterol Fumarate	16	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	15	suppressed
Cilostazol	Cilostazol	15	suppressed
Ibuprofen	Ibuprofen	15	suppressed
Propranolol Hcl	Propranolol Hcl	15	suppressed
Ventolin Hfa	Albuterol Sulfate	15	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	14	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	14	suppressed
Azelastine Hcl	Azelastine Hcl	14	suppressed
Dexlansoprazole Dr	Dexlansoprazole	14	suppressed
Entresto	Sacubitril/Valsartan	14	suppressed
Ezetimibe-Simvastatin	Ezetimibe/Simvastatin	14	suppressed
Insulin Syringe	Syringe And Needle,insulin,1ml	14	suppressed
Nebivolol Hcl	Nebivolol Hcl	14	suppressed
Ondansetron Hcl	Ondansetron Hcl	14	suppressed
Solifenacin Succinate	Solifenacin Succinate	14	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	14	13
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	14	suppressed
Aimovig Autoinjector	Erenumab-Aooe	13	suppressed
Baclofen	Baclofen	13	suppressed
Clonazepam	Clonazepam	13	suppressed
Desloratadine	Desloratadine	13	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	13	suppressed
Praluent Pen	Alirocumab	13	suppressed
Raloxifene Hcl	Raloxifene Hcl	13	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Creon	Lipase/Protease/Amylase	12	suppressed
Glipizide Er	Glipizide	12	suppressed
Metronidazole	Metronidazole	12	suppressed
Propranolol Hcl Er	Propranolol Hcl	12	suppressed
Topiramate	Topiramate	12	suppressed
Benazepril Hcl	Benazepril Hcl	11	suppressed
Candesartan-Hydrochlorothiazid	Candesartan/Hydrochlorothiazid	11	suppressed
Cartia Xt	Diltiazem Hcl	11	suppressed
Colestipol Hcl	Colestipol Hcl	11	suppressed
Dapagliflozin	Dapagliflozin Propanediol	11	suppressed
Enalapril Maleate	Enalapril Maleate	11	suppressed
Fesoterodine Fumarate Er	Fesoterodine Fumarate	11	suppressed
Humulin N	Insulin Nph Human Isophane	11	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Linzess	Linaclotide	11	suppressed
Nadolol	Nadolol	11	suppressed
Nitroglycerin	Nitroglycerin	11	suppressed
Repaglinide	Repaglinide	11	suppressed
Tadalafil	Tadalafil	11	suppressed
Tobramycin	Tobramycin	11	11

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$46.03 · 3 records	AstraZeneca Pharmaceuticals LP	AIRSUPRA, FARXIGA, PAXLOVID	4	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Farxiga play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error